当前位置: 首页 >> 检索结果
共有 7810 条符合本次的查询结果, 用时 1.87095 秒

7541. Summaries for Patients. Cervical Cancer Screening in Average-Risk Women.

来源: Ann Intern Med. 2015年162卷12期I-28页

7542. Cervical Cancer Screening in Average-Risk Women: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians.

作者: George F Sawaya.;Shalini Kulasingam.;Thomas D Denberg.;Amir Qaseem.; .
来源: Ann Intern Med. 2015年162卷12期851-9页
The purpose of this best practice advice article is to describe the indications for screening for cervical cancer in asymptomatic, average-risk women aged 21 years or older.

7543. Update in rheumatology: evidence published in 2014.

作者: David B Hellmann.;John B Imboden.
来源: Ann Intern Med. 2015年162卷9期W122-6页

7544. Update in pulmonary medicine: evidence published in 2014.

作者: Jess Mandel.
来源: Ann Intern Med. 2015年162卷9期W117-21页

7545. Update in perioperative medicine: evidence published in 2014.

作者: Karen F Mauck.;Karna K Sundsted.
来源: Ann Intern Med. 2015年162卷9期W111-6页

7546. Update in hematology: evidence published in 2014.

作者: Alice D Ma.
来源: Ann Intern Med. 2015年162卷9期W106-10页

7547. Update in geriatric medicine: evidence published in 2014.

作者: Randall J Morse.;Catherine E DuBeau.
来源: Ann Intern Med. 2015年162卷9期W102-5页

7548. Update in gastroenterology and hepatology: evidence published in 2014.

作者: John I Allen.;David S Weinberg.
来源: Ann Intern Med. 2015年162卷9期W96-101页

7549. Update in endocrinology: evidence published in 2014.

作者: Jennifer B Green.
来源: Ann Intern Med. 2015年162卷9期W91-5页

7550. Update in cardiology: evidence published in 2014.

作者: Daniel A Steinhaus.;Peter J Zimetbaum.
来源: Ann Intern Med. 2015年162卷9期W86-90页

7551. Update in general internal medicine: evidence published in 2014.

作者: Reena H Hemrajani.;Stephanie A Call.
来源: Ann Intern Med. 2015年162卷9期W80-5页

7552. Global Tuberculosis Control: Toward the 2015 Targets and Beyond.

作者: Emilio Dirlikov.;Mario Raviglione.;Fabio Scano.
来源: Ann Intern Med. 2015年163卷1期52-8页
Since 1990, progress has been made toward global tuberculosis (TB) control, as measured by targets set for 2015. However, TB remains a major threat to health around the world. In 2013, there were an estimated 11 million prevalent cases, and an estimated 9.0 million incident cases occurred globally. Approximately 1.5 million deaths were caused by TB, including 360,000 among people living with HIV. Substantial challenges threaten future control efforts. These include multidrug-resistant forms and co-infection with HIV, as well as other factors, such as the increased prominence of noncommunicable diseases and adverse socioeconomic conditions. Beyond 2015, TB control must be seen as both a public health imperative unto itself and a vital component of economic development plans. To that end, control strategies should exploit technical and operational innovations to improve TB control and care and should promote universal health coverage and social protection mechanisms to expand access to essential prevention, diagnostics, and treatment services while avoiding catastrophic costs incurred by patients.

7553. PCSK9 Inhibitors: A New Era in Lipid-Lowering Treatment?

作者: Miguel Cainzos-Achirica.;Seth S Martin.;John E Cornell.;Cynthia D Mulrow.;Eliseo Guallar.
来源: Ann Intern Med. 2015年163卷1期64-5页

7554. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.

作者: Eliano Pio Navarese.;Michalina Kolodziejczak.;Volker Schulze.;Paul A Gurbel.;Udaya Tantry.;Yingfeng Lin.;Maximilian Brockmeyer.;David E Kandzari.;Julia M Kubica.;Ralph B D'Agostino.;Jacek Kubica.;Massimo Volpe.;Stefan Agewall.;Dean J Kereiakes.;Malte Kelm.
来源: Ann Intern Med. 2015年163卷1期40-51页
Guidelines recommend statins as first-line therapy for dyslipidemia. Monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) is a new lipid-lowering approach.

7555. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.

作者: Stefan Zeuzem.;Reem Ghalib.;K Rajender Reddy.;Paul J Pockros.;Ziv Ben Ari.;Yue Zhao.;Deborah D Brown.;Shuyan Wan.;Mark J DiNubile.;Bach-Yen Nguyen.;Michael N Robertson.;Janice Wahl.;Eliav Barr.;Joan R Butterton.
来源: Ann Intern Med. 2015年163卷1期1-13页
Novel interferon- and ribavirin-free regimens are needed to treat hepatitis C virus (HCV) infection.

7556. ACP Journal Club: an exercise program for hands and arms improved hand function in RA controlled with medication.

作者: Lyn March.
来源: Ann Intern Med. 2015年162卷8期JC9页

7557. ACP Journal Club: review: in patients with obstructive sleep apnea, continuous positive airway pressure increases weight.

作者: Shirin Shafazand.
来源: Ann Intern Med. 2015年162卷8期JC8页

7558. ACP Journal Club: pooled RCTs: β-blockers reduce mortality in heart failure patients with sinus rhythm but not in those with AF.

作者: Jacob P Kelly.;Adrian F Hernandez.
来源: Ann Intern Med. 2015年162卷8期JC7页

7559. ACP Journal Club: after drug-eluting stent placement, 6 months of dual antiplatelet therapy was noninferior to 12 months.

作者: Debabrata Mukherjee.
来源: Ann Intern Med. 2015年162卷8期JC6页

7560. ACP Journal Club: review: in acute respiratory failure, prehospital CPAP reduces mortality and intubation rates.

作者: Ayan Sen.
来源: Ann Intern Med. 2015年162卷8期JC5页
共有 7810 条符合本次的查询结果, 用时 1.87095 秒